OS Therapies Statistics
Total Valuation
OS Therapies has a market cap or net worth of $76.22 million. The enterprise value is $67.79 million.
Important Dates
The last earnings date was Monday, August 18, 2025, after market close.
Earnings Date | Aug 18, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
OS Therapies has 31.89 million shares outstanding. The number of shares has increased by 286.83% in one year.
Current Share Class | 31.89M |
Shares Outstanding | 31.89M |
Shares Change (YoY) | +286.83% |
Shares Change (QoQ) | +18.19% |
Owned by Insiders (%) | 17.95% |
Owned by Institutions (%) | 0.72% |
Float | 23.37M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 13.56 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03
Current Ratio | 1.03 |
Quick Ratio | 0.81 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -34.22 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -163.50% |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | -222.43% |
Revenue Per Employee | n/a |
Profits Per Employee | -$3.25M |
Employee Count | 5 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.34% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -34.34% |
50-Day Moving Average | 1.88 |
200-Day Moving Average | 2.15 |
Relative Strength Index (RSI) | 60.81 |
Average Volume (20 Days) | 768,844 |
Short Selling Information
The latest short interest is 667,159, so 2.09% of the outstanding shares have been sold short.
Short Interest | 667,159 |
Short Previous Month | 524,900 |
Short % of Shares Out | 2.09% |
Short % of Float | 2.86% |
Short Ratio (days to cover) | 1.54 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -15.24M |
Pretax Income | n/a |
Net Income | -16.25M |
EBITDA | -15.13M |
EBIT | -15.24M |
Earnings Per Share (EPS) | -$0.74 |
Full Income Statement Balance Sheet
The company has $2.80 million in cash and n/a in debt, giving a net cash position of $2.80 million or $0.09 per share.
Cash & Cash Equivalents | 2.80M |
Total Debt | n/a |
Net Cash | 2.80M |
Net Cash Per Share | $0.09 |
Equity (Book Value) | 6.75M |
Book Value Per Share | 0.17 |
Working Capital | 95,942 |
Full Balance Sheet Cash Flow
Operating Cash Flow | -11.56M |
Capital Expenditures | n/a |
Free Cash Flow | -11.56M |
FCF Per Share | -$0.36 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
OS Therapies does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -286.83% |
Shareholder Yield | -286.83% |
Earnings Yield | -23.02% |
FCF Yield | -16.38% |
Analyst Forecast
The average price target for OS Therapies is $18.00, which is 653.14% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $18.00 |
Price Target Difference | 653.14% |
Analyst Consensus | Strong Buy |
Analyst Count | 3 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |